TSL Thinksmart Limited

RNS Number:1143A
Tissue Science Laboratories PLC
24 June 2004

                                                                    24 June 2004

                        Tissue Science Laboratories PLC

                        Result of Annual General Meeting

Tissue Science Laboratories plc, the medical devices company specialising in
human tissue replacement and repair, held its Annual General Meeting today at
which all resolutions referred to in the Notice of Annual General Meeting dated
14 May 2004, were passed.
                                     -Ends-

Enquiries:

TSL plc                                             Tel: 01252 333 002
Martin Hunt, Chief Executive Officer
David Jennings, Finance Director


Hogarth PR                                          Tel: 020 7357 9477
Melanie Toyne Sewell

Notes to Editors

Background on TSL
Founded in 1995 with headquarters in Aldershot, Hampshire, TSL is a medical
technology company specialising in tissue repair and replacement with a
proprietary sheet product derived from porcine dermis. TSL has launched
successfully different formulations of the product and built a development
pipeline that addresses the large and fast growing surgical implant market.  
The Company floated in November 2001 and is listed on the Alternative Investment
Market.

TSL has a family of products based on the same core technology.  Each product
has been adapted, with unique properties, to make it suitable for use in
different applications.  Pelvicol/Permacol Surgical Implant (SI) is sold by Bard
in the US and Europe for urology and gynaecology applications; Permacol SI
(general surgery) is sold for complex hernia repair in the US and Europe;
Permacol SI (ENT, plastic and reconstruction) is sold in Europe for head and
face applications; Permacol Injection (UBA) is an injectable form of Permacol
used as a urethral bulking agent to treat female stress incontinence.  The
Company has also recently signed a worldwide distribution agreement with Zimmer
for the application of Permacol (SI) in the orthopaedic market.  Further
variations of the sheet and injectable forms of Permacol are being developed.
Bard is a trademark of C.R. Bard, Inc. or an affiliate.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RAGMGGZVDDVGDZM

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Lug 2023 a Lug 2024